The Effect on Prognosis of Postoperative CA 19-9 Level in Patients With Pancreatic Cancer

被引：1
|
作者：
Kilickap, Saadettin [1 ]
Arslan, Cagatay [1 ]
机构：
[1] Hacettepe Univ, Inst Oncol, Dept Med Oncol, Ankara, Turkey
来源：
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2010年 / 33卷 / 03期
关键词：
RECURRENCE; ADENOCARCINOMA; SURVIVAL;
D O I：
10.1097/COC.0b013e31819fe1ff
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：320 / 320
页数：1
相关论文
共 50 条
  • [21] CA 19-9 in pancreatic cancer - from diagnosis to therapy
    Rainer, Klapdor
    TUMOR BIOLOGY, 2006, 27 : 19 - 19
  • [22] CA 19-9 and Lewis Antigens in Pancreatic Cancer Reply
    Berger, Adam C.
    Hoffman, John P.
    Winter, Kathryn
    Regine, William
    Safran, Howard
    Abrams, Ross
    Willet, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) : 2573 - 2573
  • [23] Prognostic value of CA 19-9 level in resectable pancreatic adenocarcinoma
    Rudnicki, J.
    Agrawal, A. K.
    Grzebieniak, Z.
    Zukrowski, P.
    Zysko, D.
    Jelen, M.
    Kielan, W.
    Sebastian, M.
    Slonina, J.
    Marek, G.
    Duda-Barcik, L.
    FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2010, 48 (02) : 249 - 261
  • [24] Doubling time of serum CA 19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis
    Nishida, K
    Kaneko, T
    Yoneda, M
    Nakagawa, S
    Ishikawa, T
    Yamane, E
    Nishioka, B
    Miyamoto, Y
    Takano, H
    Yoshikawa, T
    Kondo, M
    JOURNAL OF SURGICAL ONCOLOGY, 1999, 71 (03) : 140 - 146
  • [25] Prognostic impact of preoperative serum CA 19-9 level in pancreatic cancer: a pooled analysis
    Mattiucci, G. C.
    Morganti, A. G.
    Farioli, A.
    Frakulli, R.
    Cellini, F.
    Arcelli, A.
    Bertini, F.
    Forni, F.
    Fuccio, L.
    Farina, E.
    Ronchi, L.
    Guido, A.
    Macchia, G.
    Cammelli, S.
    Falconi, M.
    Valentini, V.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S78 - S78
  • [26] Interfering Effect of Black Tea Consumption on Diagnosis of Pancreatic Cancer by CA 19-9
    Al-Janabi A.A.H.S.
    Tawfeeq E.F.
    Journal of Gastrointestinal Cancer, 2017, 48 (2) : 148 - 150
  • [27] Pretreatment level of CA 19-9 is a prognostic factor in advanced pancreatic cancer treated with chemotherapy
    Gansl, R. C.
    Reis, P. T.
    Tabacof, J.
    Simon, S. D.
    Machado, M. C.
    Borghesi, G.
    Saad, E. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Sialyl Lewis(a) ganglioside in pancreatic cancer tissue correlates with the serum CA 19-9 level
    Hamanaka, Y
    Hamanaka, S
    Suzuki, M
    PANCREAS, 1996, 13 (02) : 160 - 165
  • [29] CA 125 AND CA 19-9 AS TUMORAL MARKERS IN PANCREATIC-CANCER
    PASQUALI, C
    SPERTI, C
    DANDREA, AA
    PETRIN, P
    PEDRAZZOLI, S
    ITALIAN JOURNAL OF GASTROENTEROLOGY, 1986, 18 (04): : 235 - 235
  • [30] CA 19-9, miR-200 and GIP in patients with diabetes and pancreatic cancer
    Skrha, P.
    Horinek, A.
    Andel, M.
    Fric, P.
    Skrha, J.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S452 - S452
12345